Alkermes’ Orexin-2 Receptor Agonist for Narcolepsy Enters Phase 2 Trials
The phase 2 trial will evaluate the safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in patients with narcolepsy type 1.
The phase 2 trial will evaluate the safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in patients with narcolepsy type 1.
The unique properties of vortex airflow could also be leveraged for CPAP therapy.
Quality sleep can be hard to come by during a heat wave, especially for those who don’t have air conditioning.
Topics include lemborexant's impact on daytime alertness in individuals with insomnia, its efficacy in older adults, and the process for transitioning patients from Z-drugs to Lemborexant.
Sunrise has partnered with Prevent Dementia to bring together research on mild-life risk factors for Alzheimer’s disease with Sunrise's sleep monitoring expertise.
The newly appointed CEO succeeds co-founder Shawn Regan, who steps into the chairman role.